Early Pandemic Evaluation and Enhanced Surveillance of the coronavirus COVID-19 (EAVE II)

Early Pandemic Evaluation and Enhanced Surveillance of COVID-19 (EAVE II): an observational study using linked Scottish national data

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ISRCTN

Registry ID

ISRCTN40292537

Enrollment

5400000

Registered

2020-11-17

Start date

2020-04-01

Completion date

Unknown

Last updated

2022-06-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19 (SARS-CoV-2 infection) Infections and Infestations COVID-19 (SARS-CoV-2 infection)

Interventions

This is an observational study, no intervention will be given to patients. Any vaccine programmes implemented in Scotland will be assessed for effectiveness. The study will assess these vaccine progra

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: All (anonymised) patient data will be collected

Exclusion criteria

Exclusion criteria: Does not meet inclusion criteria

Design outcomes

Primary

Measure	Time frame
1. Laboratory confirmed SARS-CoV-2 measured using virological/serological tests between baseline and 9 months 2. Serum from blood samples taken from biochemistry tests (or rapid antibody tests if available) will be used to determine exposure to SARS-CoV-2 infection by the presence of antibodies between baseline and 9 months 3. SARS-CoV-2 infection-related clinical outcomes including general practice, COVID-19 centres and out-of-hours consultations, hospital admissions including secondary bacterial infections and multidrug-resistant bacteria associated with these infections, emergency admissions, out of hours consultations, and deaths between baseline and 9 months	—

Measure

Time frame

1. Laboratory confirmed SARS-CoV-2 measured using virological/serological tests between baseline and 9 months 2. Serum from blood samples taken from biochemistry tests (or rapid antibody tests if available) will be used to determine exposure to SARS-CoV-2 infection by the presence of antibodies between baseline and 9 months 3. SARS-CoV-2 infection-related clinical outcomes including general practice, COVID-19 centres and out-of-hours consultations, hospital admissions including secondary bacterial infections and multidrug-resistant bacteria associated with these infections, emergency admissions, out of hours consultations, and deaths between baseline and 9 months

—

Secondary

Measure	Time frame
1. Vaccine uptake proportions measured using primary care practice and hospital data between baseline and 18 months 2. Prevention and reduction of SARS-CoV-2 infection-related general practice consultations, hospital admissions including secondary bacterial infections, emergency admissions, out of hours consultations and deaths due to therapies, vaccines, and antimicrobials between baseline and 18 months 3. Adverse events related to therapies, for example, vaccine, antimicrobial administration, or other therapies measured using participant data between baseline and 18 months	—

Measure

Time frame

1. Vaccine uptake proportions measured using primary care practice and hospital data between baseline and 18 months 2. Prevention and reduction of SARS-CoV-2 infection-related general practice consultations, hospital admissions including secondary bacterial infections, emergency admissions, out of hours consultations and deaths due to therapies, vaccines, and antimicrobials between baseline and 18 months 3. Adverse events related to therapies, for example, vaccine, antimicrobial administration, or other therapies measured using participant data between baseline and 18 months

—

Countries

Scotland, United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026